Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

7(87.5%)

Phase 1

1(12.5%)

8Total

Phase 2(7)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02462603Phase 2Completed

Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

Role: lead

NCT02360436Withdrawn

Analysis of the Glutathione Cycle in Children With Rett Syndrome

Role: lead

NCT02226458Phase 2Withdrawn

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

Role: lead

NCT02257983Phase 2Completed

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

Role: lead

NCT02104336Phase 2Terminated

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Role: lead

NCT01822249Phase 2Completed

Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

Role: lead

NCT01923584Phase 2Completed

A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease

Role: collaborator

NCT01962363Phase 2Completed

EPI-743 in Friedreich's Ataxia Point Mutations

Role: collaborator

NCT02300753Unknown

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Role: lead

NCT01719523Phase 1Completed

Open-Trial of EPI-743 for Adults With Tourette Syndrome

Role: collaborator

All 10 trials loaded